Objective: To evaluate the safety and effectiveness of the Stem Cell Regenera Treatment for oocyte activation in women with ovarian failure in routine clinical practice Design: Retrospective observational study From January 2023 to December 2024 Setting: IVIRMA Alicante Clinics, Spain. Population or Sample: Women diagnosed with ovarian failure including Poor Ovarian Response, Diminished Ovarian Reserve and Premature Ovarian Insufficiency. Methods: The study involved mobilizing Hematopoietic stem cells from bone marrow into peripheral blood using granulocyte colony-stimulating factor, followed by intraovarian injection of Stem Cell Factor-enriched Platelet Rich Plasma. Effectiveness was assessed by correlating leukocytes and CD34+ on day five with oocyte activation criteria and safety assesed by clinical and bilogical parameters. Main Outcome Measures: The primary outcome measures were effectiveness assessed by the rate of oocyte activation, leucocytes and stem cells count, and pregnancy rates. Oocyte activation was defined as an increase in total Antral Follicle Count of three or more follicles after treatment and/or at least a 20% rise in Anti-Müllerian Hormone levels. Safety was assessed based on adverse effects of treatment. Pregnancy rates were evaluated both for spontaneous gestation and following in vitro fertilization treatment. Results: A total of 145 women were included. The overall activation rate was 68.28%, with 7.07% achieving spontaneous gestation and 14.14% achieving pregnancy following IVF. Mobilization of CD34+ cells was successful in all participants, with an average collection of 32.96 CD34+ cells/ µl and no severe adverse effects were observed. Conclusions: The Stem Cell Regenera Treatment is effective and safe for oocyte activation in women with ovarian failure in routine clinical practice